依达拉奉治疗原发性肾病综合征的疗效观察

Therapeutic Effect of Edaravone on Primary Nephrotic Syndrome

目的:探讨依达拉奉对原发性肾病综合征(PNS)患者的治疗作用。方法:50例PNS患者随机分对照组及治疗组。治疗组除加用依达拉奉外,两组其他治疗措施完全相同。对所有患者在治疗前、缓解期进行24 h尿蛋白定量的测定,并观察患者治疗前后脂质过氧化产物丙二醛(MDA)的变化。结果:治疗组经依达拉奉治疗后MDA含量显著降低(P<0．05),治疗组疗效显著优于对照组(P<0．05)。结论:用依达拉奉治疗原发性肾病综合征患者可使MDA显著降低,减少尿蛋白的丢失明显优于对照组(P<0．01)。

Objective： To study the effects of edaravone on PNS patients. Method： Fifty patients with PNS were divided into 2 groups randomly, one as control group and the other as the treatment group. The treatment group was treated with edaravone and other therapies of the two groups were identical. All patients were examined 24 hours urinary protein content before treatment and during the relieving stage. Observed the change of MDA before and after treatment. Result： After treatment, MDS level were lower obviously in the treatment group （ P 〈 0.05 ） ; the therapeutic effect of the treatment group was better than the control group （ P 〈 0.05 ）. Conclusion： PNS patients in the treatment group acquire significant MDA reduction and less lost of urinary protein than the control group（ P 〈 0.01 ） after edaravoue therapy.